Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.

Become a Member
SFPM Reception

AACR Annual Meeting 2023

ADT01 - Functional Precision Medicine in Oncology

Please come, and encourage others. The AACR keeps track of attendance at these symposia, and if you want to raise the profile of functional precision medicine, come and bring as many with you as possible! Spread the good word of FPM.

WHEN & WHERE

Tuesday, April 18, 2023, at 10:15 AM - 11:45 AM
Tangerine Ballroom 2, Convention Center

SYMPOSIUM CHAIR

Anthony Letai, MD, PhD, Dana Farber Cancer Institute

LINE UP

  • Pamela Becker, City of Hope: Utilization of functional precision medicine for clinical trials in acute leukemia and multiple myeloma: Correlation with molecular data
  • Alana Welm, University of Utah: Feasibility of using patient-derived models for functional precision medicine in breast cancer trials
  • Philipp Staber, Medical University of Vienna: Single cell functional testing to guide treatment in aggressive hematologic malignancies

MS TB05.01:  Novel Targets, Biomarkers, and Models for Cancer

WHEN & WHERE

Tuesday, April 18, 2023, at 2:30 PM - 4:30 PM
Room W304 A-D, Convention Center

PRESENTED BY

Wojciech Senkowski, University of Copenhagen

A platform utilizing high-grade serous ovarian cancer organoids for prospective patient stratification in functional precision medicine

Membership

The SFPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits

Applications for membership may be submitted at any time during the year. We look forward to having you onboard!

Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series should not be missed for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

We are working on securing our next speaker, please check back soon.

Recent News

Stay connected, stay ahead. Know everything that matters, as it happens. From the very latest industry news, reports, papers, and studies. Would you like to see your news here? Email the admin and we will get it linked. Check out our news archive for all past stories and posts.

Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma
May 11, 2023

Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma

The current issue of Nature Reviews Cancer features on its cover a personal perspective on the fight against rare cancers. One part of the story of this features the use of an agnostic drug-repurposing screen to do functional precions medicine. This revealed vulnerabilities that were not predicted by the transcriptome, but which helped not only elucidate some important cell biology pathways in the toumor, but have laid the foundation for a clinical trial

Read MORE
A path to translation: How 3D patient tumor avatars enable next generation precision oncology
May 10, 2023

A path to translation: How 3D patient tumor avatars enable next generation precision oncology

3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.

Read MORE
Early Functional Precision Medicine Approaches Show Potential to Improve Patient Outcomes
May 9, 2023

Early Functional Precision Medicine Approaches Show Potential to Improve Patient Outcomes

Although functional precision medicine has the potential to transform cancer care, experts at the American Association for Cancer Research's annual meeting recounted how the present regulatory and reimbursement environment has made it difficult for them to use research findings to inform patient treatment.

Read MORE
Functional Precision Medicine in Oncology
May 8, 2023

Functional Precision Medicine in Oncology

Professor Anthony Letai, President of the Society for Functional Precision Medicine explains the concept of functional precision medicine in oncology: we take the patient's living tissue and expose it to drugs, then ask if there is an effect, we can measure that predicts response in vivo. Dr. Letai is convinced that this will be a valuable diagnostic tool, the next step in precision medicine.

Read MORE
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates
May 3, 2023

Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates

Drug testing of patient derived tumor organoids identified high sensitivity to the EGFR targeting drug lapatinib, consistent with HER2 amplification.  Remarkably, this patient achieved a complete remission with a combination of EGFR inhibitor trastuzumab and pertuzumab followed by a personalized vaccine, and is currently disease free.  This study indicates the potential of functional testing of patient derived tumor cells to identify effective therapies for cancers with poor outcome.

Read MORE
Promises and challenges of organoid-guided precision medicine
May 2, 2023

Promises and challenges of organoid-guided precision medicine

Organoids are self-organizing, expanding 3D cultures derived from stem cells. Using tissue derived from patients, these miniaturized models recapitulate various aspects of patient physiology and disease phenotypes, including genetic profiles and drug sensitivities

Read MORE

Support the SFPM

The SFPM is growing, and we need financial support. While we collect annual individual membership dues, these only fund a fraction of our needs. To plan for the future, the SFPM must secure a stable financial basis from which to plan. Even though the Board is made up of unpaid volunteers, we nonetheless have significant costs to defray, particularly with respect to annual meetings and administrative support.

Contributions from all tiers will be recognized by name on the SFPM website, however, contributions at the Precision tier will receive preferred logo placement and recognition on the SFPM website, logo and name recognition at each monthly seminar, and institution name and logo prominently displayed at our annual meeting and on meeting marketing materials. Precision tier supporters will also receive ten (10) complimentary memberships to be distributed amongst their institutions. Functional tier supporters will receive name and logo recognition during at least six of our monthly seminars as well as name and logo recognition on our website. Functional tier supporters will also receive five (5) complimentary memberships to be distributed amongst their institutions. Advocate tier supporters will receive name and logo recognition on our website and one (1) complimentary membership. We hope you agree with us that “the future is functional”, and that the SFPM is getting us there faster.

Thank You Sponsors